Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:
Listing of Claims

Claims 1-16 (Cancelled).

17. (Currently Amended) A method for prevention and/or treatment of fatty liver or hepatic disease, comprising administering a compound of the formula (1):

[Chemical Formula 3]

$$R^{1}O$$
 R^{2}
 t -Bu
 R^{3}
 t -Bu
 t -Bu
 t -Bu

where

 \mathbb{R}^1 is a hydrogen atom, an acyl group, or an arylalkoxycarbonyl group; and

 R^2 and R^3 are each independently a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, or a substituted or unsubstituted alkynyl group, or R^2 and R^3 may jointly form a cycloalkyl group,

to a patient in need of such prevention and/or treatment.

Appln. No. 10/573,036 Amd. dated April 10, 2008 Reply to Office Action of January 11, 2008

- 18. (Currently Amended) The $\underline{\text{method composition}}$ according to claim 17, wherein R^1 is a hydrogen atom.
- 19. (Currently Amended) The $\underline{methodeomposition}$ according to claim 17, wherein R^2 and R^3 are each an unsubstituted alkyl group.
- 20. (Currently Amended) The <u>methodcomposition</u> according to claim 17, wherein the unsubstituted alkyl group is an n-butyl group, an n-pentyl group, an n-hexyl group, or an n-heptyl group.
- 21. (Currently Amended) The methodeomposition according to claim 17, wherein the compound of the formula (1) is 4,6-di-t-butyl-5-hydroxy-2,2-di-n-butyl-2,3-dihydrobenzofuran, 4,6-di-t-butyl-5-hydroxy-2,2-di-n-pentyl-2,3-dihydrobenzofuran, 4,6-di-t-butyl-5-hydroxy-2,2-di-n-hexyl-2,3-dihydrobenzofuran, or 4,6-di-t-butyl-5-hydroxy-2,2-di-n-heptyl-2,3-dihydrobenzofuran.
- 22. (Currently Amended) The <u>method</u>composition according to claim 17, wherein the compound of the formula (1) is 4,6-di-t-butyl-5-

hydroxy-2,2-di-n-pentyl-2,3-dihydrobenzofuran.

Appln. No. 10/573,036 Amd. dated April 10, 2008 Reply to Office Action of January 11, 2008

- 23. (Currently Amended) The <u>methodeomposition</u> according to claim 17, wherein the prevention and/or treatment of hepatic disease are or is ascribed to leakage of hepatic enzymes.
- 24. (Currently Amended) The <u>method</u>composition according to claim 17, wherein the fatty liver is nonalcoholic fatty liver.
- 25. (Currently Amended) The <u>method</u>composition according to claim 17, wherein the hepatic disease is hepatic disease associated with the fatty liver.
- 26. (Currently Amended) The <u>method</u>composition according to claim 17, wherein the fatty liver is nonalcoholic fatty liver.
- 27. (Currently Amended) The <u>methodcomposition</u> according to claim 17, wherein the hepatic disease is bacterial or chemical-induced hepatic function disorder.

Appln. No. 10/573,036 Amd. dated April 10, 2008 Reply to Office Action of January 11, 2008

- 28. (Currently Amended) The <u>method composition</u> according to claim 17, wherein the hepatic disease is chronic or acute hepatitis.
- 29. (Currently Amended) The <u>methodcomposition</u> according to claim 17, wherein the hepatitis is viral.
- 30. (Currently Amended) The <u>methodeomposition</u> according to claim 17, wherein the hepatic disease is hepatic cirrhosis.
- 31. (Currently Amended) The <u>method composition</u> according to claim 17, wherein the hepatic disease is liver cancer.